# A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch

Source: https://onco.cc/trials/nct03778047/  
OnCo record `nct03778047` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Deutenzalutamide run by Hinova Pharmaceuticals Inc., completed.

## Summary

A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch is a phase 1 interventional study registered as NCT03778047 by Hinova Pharmaceuticals Inc., with 10 participants enrolled, started 2018-02-07. Conditions recorded: Metastatic Castration Resistant Prostate Cancer. Interventions recorded: Enzalutamide and HC1119.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03778047
- Phase: 1
- Setting: A Clinical Study for Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer
- Sponsor: Hinova Pharmaceuticals Inc.
- Enrolled: 10

## Sources

- ClinicalTrials.gov NCT03778047: https://clinicaltrials.gov/study/NCT03778047

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/)
- drugs: [Deutenzalutamide](https://onco.cc/drugs/deutenzalutamide/)
- companies: [Hinova Pharmaceuticals](https://onco.cc/companies/hinova-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct03778047.json